Biocryst Pharmaceuticals Inc
BCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882796
No open-market purchases or sales by Biocryst Pharmaceuticals Inc insiders were filed in the last 90 days; 319 institutions reported holding it in 13F filings for Q2 2026, worth $2.64B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +19 vs. previous quarter
- 319
- 13F valueReported value at the end of Q2 2026
- $2.64B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BCRX, Q2 2026
No superinvestor reported holding BCRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Biocryst Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 (view filing) | May 18 | 1 day | McKee Amy EDirector | SSale | −11.2K | $8.97 | −$100.3K | −26.3%31.3K after | |
| May 15, 2026 (view filing) | May 13 | 2 days | Barnes Alane PChief Legal Officer | SSale | −62.5K | $9.54 | −$596.3K | −13.5%400.7K after | 10b5-1 |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Heggie TheresaDirector | SSale | −49.9K | $10.11 | −$504.8K | −43.3%65.4K after | |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Barnes Alane PChief Legal Officer | SSale | −150.0K | $9.15 | −$1.37M | −27.2%400.7K after | 10b5-1 |
| Dec 23, 2025 (view filing) | Dec 22 | 1 day | Barnes Alane PChief Legal Officer | SSale | −21.8K | $7.65 | −$166.6K | −5.2%398.8K after | 10b5-1 |
| Dec 16, 2025 (view filing) | Dec 15 | 1 day | Barnes Alane PChief Legal Officer | SSale | −21.2K | $7.65 | −$162.3K | −6.3%315.7K after | 10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1-3 | 2 days | Barnes Alane PChief Legal Officer | SSale | −161.7K | $7.20 | −$1.16M | −31.9%345.5K after | 3 lots10b5-1 |
| Nov 17, 2025 (view filing) | Nov 13 | 4 days | Sanders MachelleDirector | SSale | −9.60K | $7.14 | −$68.5K | −23.9%30.6K after | 10b5-1 |
| Aug 15, 2025 (view filing) | Aug 13 | 2 days | Heggie TheresaDirector | SSale | −70.0K | $8.51 | −$595.7K | −51.7%65.4K after | |
| Dec 16, 2024 (view filing) | Dec 13 | 3 days | Hutson Nancy JDirector | SSale | −7.00K | $7.54 | −$52.8K | −7.5%86.6K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Biocryst Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 23,893,036 | $238.9M | 0.00% | +1,242,048+5.5% | Added |
| Ra Capital Management, L.P. | 15,827,186 | $158.3M | 1.38% | 00.0% | Unchanged |
| State Street Corp | 15,191,098 | $151.9M | 0.00% | +2,982,738+24.4% | Added |
| Deerfield Management Company, L.P. (Series C) | 15,096,403 | $151.0M | 1.57% | +58,403+0.4% | Added |
| Vanguard Capital Management LLC | 11,364,236 | $113.6M | 0.00% | +228,474+2.1% | Added |
| Vanguard Portfolio Management LLC | 11,139,158 | $111.4M | 0.01% | −105,467−0.9% | Reduced |
| TCG Crossover Management, LLC | 11,020,968 | $110.2M | 2.65% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 10,308,888 | $103.1M | 1.60% | +2,874,855+38.7% | Added |
| Jupiter Topco LLC | 9,540,764 | $95.3M | 0.04% | +9,540,764 | New |
| Vestal Point Capital, LP | 8,300,000 | $83.0M | 1.94% | +1,275,000+18.1% | Added |